Creon® (pancrelipase) therapy for subjects with exocrine pancreatic insufficiency (EPI) due to pancreatic cancer

A double-blind, randomized, parallel design with 2 dose cohorts of pancrelipase in resected pancreatic cancer subjects and an open-label single dose cohort in non-resected pancreatic cancer subjects.

Clinical Setting

Subjects with moderate to severe Exocrine Pancreatic Insufficiency due to pancreatic cancer.

Study Description

Evaluate the effects of 2 different dose levels of pancrelipase (pancreatic enzymes) on dietary fat absorption and exocrine pancreatic insufficiency (EPI) symptoms in subjects with pancreatic cancer and EPI.

Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy for Adrenocortical Carcinoma

Clinical Setting

Histologically proven metastatic adrenocortical carcinoma (ACC) evaluable by CT imaging with the majority of disease confined to the peritoneal cavity and surgically resectable to a residual size of less than 1 cm in patients who are >18 years of age.

Study Description

Phase 2 trial to determine efficacy of this therapeutic strategy in ACC. Patients will undergo cytoreductive surgery and heated intraperitoneal chemotherapy.

A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenoca

The purpose of this study is to compare the efficacy and safety of PEGPH20 combined with nab-paclitaxel & gemcitabine in participants with hyaluronan (HA)-high Stage IV previously untreated pancreatic ductal adenocarcinoma.

A Study of the Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors

This is a randomized, multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and immunogenicity of MEDI4736 in combination with tremelimumab, MEDI4736 monotherapy or tremelimumab monotherapy in subjects with metastatic or recurrent gastric or gastroesophageal junction adenocarcinoma